J&J sues over schizophrenia drug generic following patent victory

Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J fends off generic schizophrenia drug bids

10 July 2025 Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.

Americas

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies

10 June 2025 US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and Aurobindo Pharma until 2030s.

Americas

J&J unit could owe biotech $125m over AI-based surgical ‘night vision’ tech

3 June 2025 New York court finds Ethicon breached agreement with ChemImage over advanced imaging technologies | Parties dispute damages for IP ‘impairment’.

More features

Why AI is changing the patent rules faster than anyone can keep up

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

J&J sues over schizophrenia drug generic following patent victory

More on this story

Editor's picks

Editor's picks

More features